

Influenza Reagent Influenza virus infectious NYMC X-171B NIBSC code: 07/348 Instructions for use (Version 1.0, Dated 06/03/2008)

## 1. INTENDED USE

Reagent 07/348 is prepared from NYMC X-171B (A/Brisbane/10/2007 (H3N2) x A/PR/8/34 (H1N1) ) which was processed for freeze drying in 250µl volumes as described by Campbell, PJ, Journal of Biological Standardisation, 1974, 2,249-267. The known passage history of NYMC X-171B is attached

## 2. CAUTION

## This preparation is not for administration to humans or animals in the human food chain.

The material is not of human or bovine origin. As with all materials of biological origin, this preparation should be regarded as potentially hazardous to health. It should be used and discarded according to your own laboratory's safety procedures. Such safety procedures should include the wearing of protective gloves and avoiding the generation of aerosols. Care should be exercised in opening ampoules or vials, to avoid cuts.

## 3. UNITAGE

No unitage is assigned to this material

## 4. CONTENTS

Country of origin of biological material: United Kingdom. Each ampoule contains 250µl (nominal) of infectious influenza virus as allantoic fluid from SPF embryonated hen's eggs.

## 5. STORAGE

Store in the dark at -20°C or below

Please note: because of the inherent stability of lyophilized material, NIBSC may ship these materials at ambient temperature.

## 6. DIRECTIONS FOR OPENING

DIN ampoules have an 'easy-open' coloured stress point, where the narrow ampoule stem joins the wider ampoule body. Various types of ampoule breaker are available commercially. To open the ampoule, tap the ampoule gently to collect material at the bottom (labelled) end and follow manufactures instructions provided with the ampoule breaker.

## 7. USE OF MATERIAL

Reconstitute the contents of one ampoule of reagent with 250µl of sterile distilled water. Leave for a minimum of 5 minutes before use to allow for complete solution of freeze-dried material. A range of dilutions (e.g. 10<sup>-3</sup> to 10<sup>-5</sup>) should be made in a suitable medium for initial cultivation.

## 8. STABILITY

Reference Materials should be stored on receipt as indicated on the

NIBSC follows the policy of WHO with respect to its reference materials.

## **REFERENCES**

NA

#### **ACKNOWLEDGEMENTS** 10.

NA

## National Institute for Biological Standards and Control,

Potters Bar, Hertfordshire, EN6 3QG. T +44 (0)1707 641000, nibsc.org WHO International Laboratory for Biological Standards, **UK Official Medicines Control Laboratory** 

## 11. FURTHER INFORMATION

Further information can be obtained as follows:

This material: enquiries@nibsc.org

WHO Biological Standards:

http://www.who.int/biologicals/en/ JCTLM Higher order reference materials:

http://www.bipm.org/en/committees/jc/jctlm/

**Derivation of International Units:** 

http://www.nibsc.org/standardisation/international\_standards.aspx

Ordering standards from NIBSC:

http://www.nibsc.org/products/ordering.aspx

NIBSC Terms & Conditions:

http://www.nibsc.org/terms\_and\_conditions.aspx

## 12. CUSTOMER FEEDBACK

Customers are encouraged to provide feedback on the suitability or use of the material provided or other aspects of our service. Please send any comments to enquiries@nibsc.org

## 13. CITATION

In all publications, including data sheets, in which this material is referenced, it is important that the preparation's title, its status, the NIBSC code number, and the name and address of NIBSC are cited and cited

## 14. MATERIAL SAFETY SHEET

Classification in accordance with Directive 2000/54/EC, Regulation (EC) No 1272/2008: Not applicable or not classified

140 1272/2000. Not applicable of flot diagonied				
Physical and Chemical properties				
Physical appearance:		Corrosive:	No	
White powder				
Stable: Yes		Oxidising:	No	
Hygroscopic: No		Irritant:	No	
Flammable: No		Handling:Se	e caution, Section 2	
Other (specify): Live influenza virus				
Toxicological properties				
Effects of inhalation: Like		nood of influe	enza virus infection	
Effects of ingestion: Not		stablished, a	void ingestion	
Effects of skin absorption: No		stablished, a	void contact with skin	
Suggested First Aid				
Inhalation: Seek	Seek medical advice			
Ingestion: Seek medical advice				
Contact with eyes: Wash with copious amounts of water. Seek medical advice				
Contact with skin: Wash thoroughly with water.				
Action on Spillage and Method of Disposal				

## Action on Spillage and Method of Disposal

Spillage of ampoule contents should be taken up with absorbent material wetted with a virucidal agent. Rinse area with virucidal agent followed by water.

Absorbent materials used to treat spillage should be treated as biologically hazardous waste

## 15. LIABILITY AND LOSS

In the event that this document is translated into another language, the English language version shall prevail in the event of any inconsistencies between the documents.

Unless expressly stated otherwise by NIBSC, NIBSC's Standard Terms and Conditions for the Supply of Materials (available at http://www.nibsc.org/About\_Us/Terms\_and\_Conditions.aspx



request by the Recipient) ("Conditions") apply to the exclusion of all other terms and are hereby incorporated into this document by reference. The Recipient's attention is drawn in particular to the provisions of clause 11 of the Conditions.

# 16. INFORMATION FOR CUSTOMS USE ONLY

Country of origin for customs purposes\*: United Kingdom

\* Defined as the country where the goods have been produced and/or sufficiently processed to be classed as originating from the country of supply, for example a change of state such as freeze-drying.

Net weight: NA

Toxicity Statement: Non-toxic

Veterinary certificate or other statement if applicable.

Attached: No

## **Derivation of NYMC X-171B (Post mixed infection)**

Passage	Lot	Laboratory
E1 – E7		NYMC, New York, USA
E8	E5742	NYMC, New York, USA
E9(SPF)	29330	NIBSC, Hertfordshire, UK



Nov. 26, 2007

# 

Exper. # 4622 (9/20/07) A/Brisbane/10/2007 (H3N2) (CDC#2007731495) recd. from CDC 9/11/07 E2/E1 (8/20/07) HA:128

Post-reassortant Passage No.	A/Brisbane/10/2007 X A/PR/8/34
	10 <sup>-1</sup> + 10 <sup>-4</sup>
	<u>HA—1024</u> C*
1	10 <sup>-1</sup> + A/PR/8/34 As A/PR/8/34 N1 As <u>HA—128</u> C*
2	10 <sup>-1</sup> + A/PR/8/34 HANA Abs A/PR/8/34 N1 As HA—512 C*
3	+ A/PR/8/34 HANA Abs A/PR/8/34 N1 As
	<u>HA—256</u> C*
4	10 <sup>-1</sup>
	<u>HA</u> —64 C*
5	10 <sup>-1</sup>
	<u>HA8</u> C*
6	10 <sup>-4</sup>
7	10 <sup>-8</sup>
	<u>HA</u> —1024 C*

 $\label{local-prop} $$\lambda = 10.07.genealogy.11.26.07.doc $$ \end{tikzpicture} The property of t$ 



Nov. 26, 2007



X-171 E#5742 NYMC archive Sent to CDC 11/14/07

- C\* Chicken red blood cells, room temp.
- --HA and NA identified as A/Brisbane/10/2007 serologically by HI and NI tests and by RT-PCR/RFLP analysis of HA and NA genes.
- --PB2, PB1, PA, NP, M and NS genes were identified as A/PR/8/34 by RT-PCR/RFLP analysis. Therefore X-171 is a 6:2 reassortant (6 PR/8 genes and remaining 2 genes HA and NA--from Brisbane)
- --SPAFAS eggs were used exclusively for all passages.

 $\label{local-prop} $$\lambda = 10.07.genealogy.11.26.07.doc $$ \end{tabular} $$$ \end{tabular} $$$ \end{tabular} $$$ \end{tabular$ 

National Institute for Biological Standards and Control, Potters Bar, Hertfordshire, EN6 3QG. T +44 (0)1707 641000, nibsc.org WHO International Laboratory for Biological Standards,

UK Official Medicines Control Laboratory